C3AR1 Gene Expression Measurement for Infection Risk Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical diagnostic tests lack the ability to identify patients at high risk of developing healthcare-associated infections, which are a significant complication in healthcare settings, leading to increased morbidity, mortality, and healthcare costs.
Innovation Solution
A method involving the measurement of C3AR1 gene expression in biological samples to determine the risk of complications, including healthcare-associated infections, by assessing the expression of C3AR1 and other relevant genes in patients within healthcare facilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current clinical diagnostic tests are used, then general patient monitoring is available, but the ability to identify patients at high risk of healthcare-associated infections is lacking
Solution Approach 1:
The patent extracts and measures the expression level of a specific gene (C3AR1) from the complex biological system to identify patients at risk of healthcare-associated infections. This extraction of a key biomarker enables precise risk identification without requiring complex multi-parameter diagnostic systems.
Solution Approach 2:
The patent changes the measurement parameter from general clinical indicators to specific gene expression levels (C3AR1). This parameter change enables early and accurate identification of patients at high risk of infections, transforming the diagnostic capability from non-specific to highly specific.
2Reliability
If early identification of high-risk patients is achieved, then mortality and healthcare costs can be reduced, but no current clinical in vitro diagnostic test provides this capability
Solution Approach 1:
The patent performs preliminary measurement of C3AR1 gene expression to identify patients at risk of healthcare-associated infections before the infections develop. This preliminary action enables early intervention and prevention, improving patient outcomes by addressing the risk before it manifests as actual infection.
Solution Approach 2:
The patent uses C3AR1 gene expression as an intermediary biomarker that mediates between the complex immune response system and the clinical diagnosis of infection risk. This intermediary provides a measurable indicator that reflects the underlying biological processes without requiring direct measurement of complex immune responses.
3Loss of information
If comprehensive patient monitoring is implemented, then more information about patient status is available, but the identification time for high-risk patients remains prolonged
Solution Approach 1:
The patent extracts the critical information needed for risk identification (C3AR1 gene expression level) from the comprehensive patient data set. This extraction focuses measurement on the most relevant biomarker, providing complete information about infection risk without the time cost of analyzing all possible patient parameters.
Solution Approach 2:
The patent establishes a preliminary diagnostic marker (C3AR1 expression) that can be measured early in the patient's hospital course to identify high-risk individuals. This preliminary action reduces identification time by providing a focused measurement that delivers complete risk assessment information without requiring prolonged monitoring.
Data Source
AI summary
An in vitro or ex vivo method for determining the risk of complication in a patient, including a step of measuring the expression of C3AR1 in a biological sample from the patient.